Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: Clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components

American Journal of Hematology

Volumn 88, Issue 3, 2013, Pages 219-224

  Wang, Sa A ^a   Hutchinson, Lloyd ^b   Tang, Guilin ^a   Chen, Su S ^a   Miron, Patricia M ^b   Huh, Yang O ^a   Jones, Dan M ^c   Bueso Ramos, Carlos ^a   Verstovsek, Srdan ^a   Medeiros, L Jeffrey ^a   Miranda, Roberto N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ATM PROTEIN; BORTEZOMIB; CD2 ANTIGEN; CLADRIBINE; CORTICOSTEROID; DASATINIB; IMATINIB; INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; LENALIDOMIDE; PURINE DERIVATIVE; RITUXIMAB; STEM CELL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; BONE MARROW CELL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLONAL VARIATION; CORTICOSTEROID THERAPY; DISEASE SPECIFIC SURVIVAL; EOSINOPHILIC LEUKEMIA; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE DELETION; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MAST CELL; MAST CELL LEUKEMIA; MULTIPLE MYELOMA; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; PLASMACYTOMA; PRIORITY JOURNAL; PYROSEQUENCING; QUANTITATIVE ANALYSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SKIN DEFECT; SYSTEMIC MASTOCYTOSIS; SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED CLONAL HEMATOLOGICAL NONMAST CELL LINEAGE DISEASE; TRISOMY 8; WALDENSTROEM MACROGLOBULINEMIA;

EID: 85027957783     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23380     Document Type: Article

References (20)

1. Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: State of the art. Br J Haematol 2003;122:695-717.
2. Horny H-PMD BJ, Bain BJ, Akin C, et al. Mastocytosis (Mast Cell Disease). Geneva: IARC Press; 2008.
3. Horny DDM, Bennett JM, Bain BJ, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: International Agency for Research on Cancer; 2008. pp 54-63.
4. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors. Blood 2009;113:5727-5736.
5. Pardanani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009;114:3769-3772.
6. Johnson MR, Verstovsek S, Jorgensen JL, et al. Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Mod Pathol 2009;22:50-57.
7. Horny HP, Sotlar K, Sperr WR, et al. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: A histopathological challenge. J Clin Pathol 2004;57:604-608.
8. Kirshenbaum AS, Goff JP, Semere T, et al. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 1999;94:2333-2342.
9. Robyn J, Metcalfe DD. Systemic mastocytosis. Adv Immunol 2006;89:169-243.
10. Akin C. Molecular diagnosis of mast cell disorders: A paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006;8:412-419.
11. Sotlar K, Colak S, Bache A, et al. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol 2010;220:586-595.
12. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366-2372.
13. Zhao W, Bueso-Ramos CE, Verstovsek S, et al. Quantitative profiling of codon 816 KIT mutations can aid in the classification of systemic mast cell disease. Leukemia 2007;21:1574-1576.
14. Kim Y, Weiss LM, Chen YY, Pullarkat V. Distinct clonal origins of systemic mastocytosis and associated B-cell lymphoma. Leuk Res 2007;31:1749-1754.
15. Pullarkat V, Bedell V, Kim Y, et al. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res 2007;31:261-265.
16. Bernd HW, Sotlar K, Lorenzen J, et al. Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature. J Clin Pathol 2004;57:324-328.
17. Sotlar K, Bache A, Stellmacher F, et al. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: A distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F. J Mol Diagn 2008;10:58-66.
18. Nagai S, Ichikawa M, Takahashi T, et al. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia. Exp Hematol 2007;35:1747-1752.
19. Pozdnyakova O, Stachurski D, Hutchinson L, et al. Trisomy 8 in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 2008;183:49-52.
20. Vigil CE, Wang SA, Cortes JE, et al. Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase. J Clin Oncol 2011;29:e514-e516.